Recent Advances in Biomarker Technologies, Radiopharmaceuticals and Biologics

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides insights into recent technological developments for molecular marker detection, drug delivery, cancer immunotherapies and radiopharmaceuticals. The TOE also comprises analysis of innovations across cell and gene therapy, antibody and gene editing platforms.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Spatial Proteomics, Multiplexed Single-Cell Protein Mapping, DNA Sequencing, thrombosis, inflammatory diseases, Microbiome Profiling, AI-Driven Genomics, spatial-omics, nanomedicine, targeted delivery, cancer immunotherapy, neurology, skin disease, Bioorthogonal Click-to-Release Platform, Trigger-Controlled Therapeutic Payload Activation, targeted drug delivery, Circular Single-Stranded DNA, gene editing, cell and gene therapy, CAR-T, cancer, T cell therapy, Spatial Proteomics, single cell proteomics, alpha therapy, tumor retention, antibody therapy, radiotherapy, radioantibody, prostate cancer, radiopharmaceuticals, Painless Transdermal Injection, petide delivery, blood brain barrier, non-viral gene therapy, PCSK9 Inhibitor, agentic AI, MeDRA Coding, autologous therapy, stem cell therapy, cardiomyopathy, small molecule, CRSIPR, Drug Discovery, Gene Editing, Gene Therapy